Nabriva Therapeutics has appointed Will Sargent in the newly created position of vice president of commercial strategy and investor relations.
Sargent has over twenty years of experience in the biopharmaceutical industry, including multiple product and line extension launches. His most recent position was as VP of the orthopaedic business unit at Auxilium Pharmaceuticals.
Nabriva is currently moving rapidly to advance its lead product, lefamulin, into phase III clinical studies which are expected to begin enrolling in 2015 and 2016.
He said: “I am excited to join this talented and dedicated team focused on advancing a novel, targeted antibiotic therapy that can impact patients’ lives by addressing an unmet medical need.
“I look forward to applying my experience toward the successful development and implementation of the lefamulin commercial strategy and expansion of corporate communications.”
Dr Colin Broom, CEO of Nabriva, added: “Will’s strategic focus, experience and breadth of knowledge will help us plan and execute toward our commercial path goals.”